Cmst Development (600787.SS) traded flat 0 % during a 24 hours period ending at 06:39 PM Central Europe on Monday 26th. One Cmst Development stock can currently be bought for about CNY 4.64 on popular exchanges. Current supply of Cmst Development stocks is 2.2 bn. Cmst Development has a current market capitalization of CNY 9.9 bn and approximately CNY 102.2 mn worth of Cmst Development was traded on exchanges in the last 24 hours. Since last month end, Cmst Development has traded 0.44 % up. Simple moving average of last 200 days is at CNY 4.57. The highest price of past 52 weeks was recorded at CNY 6.15 on 11/14/2025. 52 weeks low was at CNY 4.05 on 06/29/2026.
Here is how related stocks have performed in the past 24 hours:
Angelalign (6699.HK) traded up 3.05 % and now trades at HKD 81.65. Current market capitalisation for Angelalign is HKD 13.9 bn. Angelalign has a current price to earnings ratio of 43.27.
Bank Of Lanzhou (001227.SZ) traded flat 0 % and now trades at CNY 2.09. Bank Of Lanzhou has a market capitalisation of CNY 11.8 bn. Bank Of Lanzhou has a current price to earnings ratio of 7.26.
Digiwin (300378.SZ) traded flat 0 % and now trades at CNY 43.47. Current market capitalisation for Digiwin is CNY 11.9 bn. Current price/earnings ratio for Digiwin is 38.67. DIGIWIN CO LTD experienced a notable increase in trading volume, setting a new high since early January. The share price slipped slightly, with turnover reflecting moderate activity. Meanwhile, market commentary highlighted strong demand for cloud computing capacity, particularly from a major U.S. provider, which has already filled orders through 2028. Analysts project continued growth in the AI infrastructure sector, with capital expenditures rising sharply. Within the broader cloud‑computing theme, several companies, including DIGIWIN, saw gains in recent weekly performance, and investor interest has grown, reflected by financing activity across the sector. The overall market sentiment points to sustained expansion of cloud and AI services, with expectations for further investment in high‑performance computing resources.
Qingdao Baheal Pharmaceuti (301015.SZ) traded flat 0 % and now trades at CNY 25.01. Current market capitalisation for Qingdao Baheal Pharmaceuti is CNY 11.9 bn. Current price/earnings ratio for Qingdao Baheal Pharmaceuti is 24.11. On October 26, 2026, Qingdao Baoyang Pharmaceutical (now announcing a name change to Baoyang Pharmaceutical Group) saw its shares rise by more than ten percent, reflecting investor optimism about a strategic shift from a distribution model to a full‑cycle pharmaceutical enterprise. The company’s announcement highlighted the acquisition of Shanghai Baoyang Pharmaceutical, the development of high‑end manufacturing capabilities, and the integration of a diversified pipeline covering oncology, cardiovascular, and rare disease areas. Market sentiment toward the broader pharmaceutical sector remained buoyant, with several other drug‑development and biotech names also posting gains, while the overall market experienced moderate volatility. The company’s rebranding signals a move toward stronger intellectual‑property assets and a more vertically integrated business structure.
China National Accord Medi (000028.SZ) traded flat 0 % and now trades at CNY 21.06. Current market capitalisation for China National Accord Medi is CNY 11.8 bn. Current price/earnings ratio for China National Accord Medi is 11.75.
About Cmst Development
CMST Development Co., Ltd. is a logistics service provider operating in the Air Freight & Logistics industry with its base in Beijing, China. The company offers various services including commodity circulation, transportation, warehousing, logistics trade, financial logistics, and logistics property services. Additionally, CMST Development also ventures into financial loans, e-commerce, and logistics technology businesses. The official website for the company is zcgf.com.cn and it is listed on the Shanghai Stock Exchange. The IPO date of the company is December 18, 1996.
